{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:55:20Z","timestamp":1791262520713,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110519","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:21:24Z","timestamp":1789744884000},"page":"110519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8055-8036","authenticated-orcid":false,"given":"Seyed Jalal","family":"Hosseinimehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110519_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.bioorg.2026.110519_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.bioorg.2026.110519_bb0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","article-title":"Gene amplification in cancer","volume":"22","author":"Albertson","year":"2006","journal-title":"Trends Genet."},{"key":"10.1016\/j.bioorg.2026.110519_bb0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","article-title":"Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.110519_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/1536012119829986","article-title":"Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using a Zirconium-89 labeled therapeutic antibody, Avelumab","volume":"18","author":"Jagoda","year":"2019","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0030","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s00259-017-3663-y","article-title":"Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer","volume":"44","author":"Jiang","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","article-title":"Clinical implications of intratumor heterogeneity: challenges and opportunities","volume":"98","author":"Ram\u00f3n","year":"2020","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","author":"S\u00f6rensen","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110519_bb0045","article-title":"Molecular imaging biomarkers for early cancer detection: a systematic review of emerging technologies and clinical applications","volume":"14","author":"Malik","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.110519_bb0055","first-page":"100","article-title":"A comparison of accuracy of planar and evolution SPECT\/CT bone imaging in differentiating benign from metastatic bone lesions","volume":"100","author":"Teyateeti","year":"2017","journal-title":"J. Med. Assoc. Thail."},{"key":"10.1016\/j.bioorg.2026.110519_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","author":"Severi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bioorg.2026.110519_bb0065","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s00259-023-06252-x","article-title":"The predictive value of pretherapy [(68)Ga]Ga-DOTA-TATE PET and biomarkers in [(177)Lu]Lu-PRRT tumor dosimetry","volume":"50","author":"Akhavanallaf","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0070","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2967\/jnumed.120.250720","article-title":"(89)Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression","volume":"62","author":"Jung","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110519_bb0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41571-024-00946-3","article-title":"Molecular imaging supports the development of multispecific cancer antibodies","volume":"21","author":"van Winkel","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/med.20002","article-title":"Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases","volume":"24","author":"Okarvi","year":"2004","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110519_bb0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imaging."},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2026.110519_bb0095","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s00259-011-2001-z","article-title":"Radiopharmaceutical development of radiolabelled peptides","volume":"39","author":"Fani","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0100","article-title":"An Evans blue-modified melanin-targeting theranostic agent for improved PET imaging and radionuclide therapy of malignant melanoma","author":"Zhou","year":"2026","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110519_bb0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/2394-4722.163151","article-title":"Growth factor receptors: promising drug targets in cancer","volume":"1","author":"Tiash","year":"2015","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.bioorg.2026.110519_bb0110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1309\/AJCPT41TCBUEVDQC","article-title":"Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens","volume":"144","author":"Furrer","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0115","first-page":"209","article-title":"Imaging of HER2 with [(89)Zr]pertuzumab in response to T-DM1 therapy","volume":"34","author":"Massicano","year":"2019","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.bioorg.2026.110519_bb0120","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-04-4472","article-title":"Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging","volume":"65","author":"Olafsen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.nucmedbio.2016.01.002","article-title":"(18)F-nanobody for PET imaging of HER2 overexpressing tumors","volume":"43","author":"Xavier","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0130","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/acs.molpharmaceut.3c00360","article-title":"Evaluation of [(89)Zr]Zr-DFO-2Rs15d nanobody for imaging of HER2-positive breast Cancer","volume":"20","author":"Ducharme","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.110519_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910745","article-title":"Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies","volume":"22","author":"Hrynchak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110519_bb0140","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123149","article-title":"Direct intra-patient comparison of scaffold protein-based tracers, [(99m)Tc]Tc-ADAPT6 and [(99m)Tc]Tc-(HE)(3)-G3, for imaging of HER2-positive breast cancer","volume":"15","author":"Bragina","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2967\/jnumed.111.093047","article-title":"Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer","volume":"53","author":"Heskamp","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00259-011-2016-5","article-title":"Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging","volume":"39","author":"Rosik","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ejmech.2017.12.037","article-title":"An improved (99m)Tc-HYNIC-(Ser)(3)-LTVSPWY peptide with EDDA\/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor","volume":"144","author":"Khodadust","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110519_bb0165","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-07-0160","article-title":"Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas","volume":"13","author":"Kumar","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0170","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2967\/jnumed.122.265364","article-title":"Human epidermal growth factor receptor 2-targeting [(68)Ga]Ga-ABY-025 PET\/CT predicts early metabolic response in metastatic breast cancer","volume":"64","author":"Alhuseinalkhudhur","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0175","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule","volume":"55","author":"S\u00f6rensen","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0180","series-title":"89Zr-nimotuzumab for potential clinical translation as an anti-EGFR immunoPET agent","author":"Chekol","year":"2017"},{"key":"10.1016\/j.bioorg.2026.110519_bb0185","doi-asserted-by":"crossref","first-page":"17117","DOI":"10.18632\/oncotarget.24965","article-title":"(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I","volume":"9","author":"Chekol","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110519_bb0190","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.18632\/oncotarget.4672","article-title":"89Zr-cetuximab PET imaging in patients with advanced colorectal cancer","volume":"6","author":"Menke-van der Houven van Oordt","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110519_bb0195","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00259-019-04555-6","article-title":"[(89)Zr]Zr-cetuximab PET\/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer","volume":"47","author":"van Helden","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2967\/jnumed.118.216069","article-title":"Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models","volume":"60","author":"Burley","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0205","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00259-010-1700-1","article-title":"Facile labelling of an anti-epidermal growth factor receptor nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET","volume":"38","author":"Vosjan","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081320","article-title":"G protein-coupled receptors in cancer","volume":"17","author":"Bar-Shavit","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2026.110519_bb0215","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1007\/s00259-011-2019-2","article-title":"Somatostatin receptor SPECT","volume":"39","author":"Pepe","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0000000000004670","article-title":"Impact of cold somatostatin analog administration on somatostatin receptor imaging: a systematic review","volume":"48","author":"Morland","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0225","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"(68)Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis","volume":"58","author":"Graham","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ph13030038","article-title":"[(68)Ga]Ga-DOTA-TOC: the first FDA-approved (68)Ga-radiopharmaceutical for PET imaging","volume":"13","author":"Hennrich","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0235","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0240","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.18632\/oncotarget.27695","article-title":"Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: a retrospective analysis in neuroendocrine tumor patients","volume":"11","author":"Chauhan","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110519_bb0245","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/RLU.0000000000001753","article-title":"Whole-body 68Ga-DOTANOC PET\/MRI versus 68Ga-DOTANOC PET\/CT in patients with neuroendocrine tumors: a prospective study in 28 patients","volume":"42","author":"Berzaczy","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0250","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/MNM.0000000000001248","article-title":"Does 68Ga-DOTA-NOC-PET\/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?","volume":"41","author":"Purandare","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.bioorg.2026.110519_bb0255","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNM.0b013e32832999c1","article-title":"68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid","volume":"30","author":"Ambrosini","year":"2009","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.bioorg.2026.110519_bb0260","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00259-024-06622-z","article-title":"Head-to-head comparison between [(68)Ga]Ga-DOTA-NOC and [(18)F]DOPA PET\/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas","volume":"51","author":"He","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17121937","article-title":"Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis in the era of somatostatin receptor PET imaging","volume":"17","author":"Maratta","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0270","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ejca.2012.10.018","article-title":"Clinical significance of intratumoral HER2 heterogeneity in gastric cancer","volume":"49","author":"Lee","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110519_bb0275","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2967\/jnumed.115.165092","article-title":"Upregulation of key molecules for targeted imaging and therapy","volume":"57","author":"Taelman","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"K\u00f6rner","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2026.110519_bb0285","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2016.12.083","article-title":"Radiolabeled bombesin derivatives for preclinical oncological imaging","volume":"87","author":"Ferreira","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110519_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin analogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0295","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin receptor antagonists may be preferable to agonists for tumor targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0300","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0305","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184537","article-title":"Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy","volume":"15","author":"Abusalem","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0315","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3892\/ol.2016.4699","article-title":"Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.110519_bb0320","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0330","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102533","article-title":"The performance of FDA-approved PET imaging agents in the detection of prostate cancer","volume":"10","author":"Li","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.110519_bb0340","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0345","article-title":"PSMA-targeted radiolabeled peptide for imaging and therapy in prostate cancer: preclinical evaluation of biodistribution and therapeutic efficacy","volume":"26","author":"Chen","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110519_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17061049","article-title":"The role of 18F PSMA-1007 PET\/CT in the staging and detection of recurrence of prostate cancer, a scoping review","volume":"17","author":"Armany","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164185","article-title":"Application of 18F-PSMA-1007 PET\/MR imaging in early biochemical recurrence of prostate cancer: results of a prospective study of 60 patients with very Low PSA levels \u2264 0.5 ng\/mL","volume":"15","author":"Mojsak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0360","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj.pcan.4500570","article-title":"Evaluation of preoperative ProstaScint scans in the prediction of nodal disease","volume":"5","author":"Ponsky","year":"2002","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bioorg.2026.110519_bb0365","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pros.20367","article-title":"A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer","volume":"66","author":"Els\u00e4sser-Beile","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.bioorg.2026.110519_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13081837","article-title":"PSMA-directed theranostics in prostate cancer","volume":"13","author":"Jajja","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.110519_bb0375","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13550-016-0164-0","article-title":"Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling","volume":"6","author":"Fung","year":"2016","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0380","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1158\/1078-0432.CCR-05-0826","article-title":"Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer","volume":"11","author":"Morris","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0385","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors","volume":"5","author":"Pandit-Taskar","year":"2015","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0390","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cncr.24795","article-title":"Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer","volume":"116","author":"Tagawa","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110519_bb0395","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","article-title":"A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate cancer","volume":"56","author":"Chatalic","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0400","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bmj.285.6353.1447","article-title":"Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen","volume":"285","author":"Berche","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0405","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.1991.9.4.631","article-title":"Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer","volume":"9","author":"Griffin","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0410","first-page":"155","article-title":"Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging","volume":"26","author":"Bohdiewicz","year":"1998","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0415","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jim4.16","article-title":"Advancements in colorectal cancer detection: the role of immuno-positron emission tomography, immuno-single-photon emission computed tomography, and machine learning applications","volume":"1","author":"Chen","year":"2024","journal-title":"J. Intell. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0420","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0425","series-title":"Molecular Imaging and Contrast Agent Database (MICAD)","article-title":"(99m)Tc-Arcitumomab","author":"Cheng","year":"2004"},{"key":"10.1016\/j.bioorg.2026.110519_bb0430","article-title":"Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0435","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-06-0266","article-title":"Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man","volume":"12","author":"Beer","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0440","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-07-0528","article-title":"[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck","volume":"13","author":"Beer","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0445","first-page":"763","article-title":"PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression","volume":"47","author":"Beer","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0450","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.RES.77.6.1129","article-title":"Alpha-v beta-3 integrin expression in normal and atherosclerotic artery","volume":"77","author":"Hoshiga","year":"1995","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioorg.2026.110519_bb0455","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0002-9440(10)63293-2","article-title":"Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis","volume":"165","author":"Antonov","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0460","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7150\/thno\/v01p0058","article-title":"Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT","volume":"1","author":"Zhou","year":"2011","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110519_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170385","article-title":"Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy","volume":"133","author":"Abbasi Gharibkandi","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.bioorg.2026.110519_bb0470","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1007\/s10967-022-08496-7","article-title":"The application value of 18F-Alfatide-RGD PET\/CT in the preliminary diagnosis of patients with non-small cell lung cancer","volume":"331","author":"Guo","year":"2022","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.bioorg.2026.110519_bb0475","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/s41598-017-03296-6","article-title":"A pilot study of (18)F-Alfatide PET\/CT imaging for detecting lymph node metastases in patients with non-small cell lung cancer","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110519_bb0480","article-title":"Potential (18)F-RGD PET\/CT and DCE-MRI imaging-based biomarkers for postoperative survival prediction among patients with newly diagnosed glioblastoma treated with bevacizumab and chemoradiotherapy","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0485","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1021\/acs.molpharmaceut.2c00547","article-title":"Combined (18)F-FDG and (18)F-Alfatide II PET may predict luminal B (HER2 negative) subtype and nonluminal subtype of invasive breast cancer","volume":"19","author":"Wu","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.110519_bb0490","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2967\/jnumed.115.160648","article-title":"68Ga-NOTA-PRGD2 PET\/CT for integrin imaging in patients with lung cancer","volume":"56","author":"Zheng","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0495","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/RLU.0000000000002233","article-title":"Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET\/CT can discriminate uncommon meningioma mimicking high-grade glioma","volume":"43","author":"Li","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/ph17111556","article-title":"Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (arginine-glycine-aspartate) strategies","volume":"17","author":"Bogdanovi\u0107","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0505","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110519_bb0510","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0969-8051(03)00080-5","article-title":"Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals","volume":"30","author":"Mathias","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0515","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/bc9500709","article-title":"Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging","volume":"7","author":"Wang","year":"1996","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2026.110519_bb0520","first-page":"1153","article-title":"Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors","volume":"47","author":"Bettio","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0525","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1021\/bc800356r","article-title":"Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative","volume":"19","author":"Ross","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2026.110519_bb0530","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1021\/bc200660z","article-title":"[18F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting","volume":"23","author":"Fischer","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2026.110519_bb0535","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1021\/acs.molpharmaceut.7b00415","article-title":"Folate-PEG-NOTA-Al(18)F: a new folate based radiotracer for PET imaging of folate receptor-positive tumors","volume":"14","author":"Chen","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.110519_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108952","article-title":"Preoperative [(18)F]fluoro-PEG-folate PET\/CT in advanced stage epithelial ovarian cancer: a safety and feasibility study","volume":"138-139","author":"Ciggaar","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0545","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0550","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007659","article-title":"First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET","volume":"12","author":"Pouw","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2026.110519_bb0555","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0560","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202400358","article-title":"Assessment of PD-L1 expression in non-small cell lung cancers using [(68)Ga]Ga-DOTA-WL12 PET\/CT","volume":"8","author":"Wu","year":"2024","journal-title":"Small Methods"},{"key":"10.1016\/j.bioorg.2026.110519_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101202","article-title":"Peptide-based PET\/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma","volume":"79","author":"Wang","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2026.110519_bb0570","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2967\/jnumed.120.258384","article-title":"Synthesis and preclinical evaluation of a (68)Ga-labeled adnectin, (68)Ga-BMS-986192, as a PET agent for imaging PD-L1 expression","volume":"62","author":"Robu","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0575","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2967\/jnumed.119.241364","article-title":"Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer (18)F-BMS-986192","volume":"61","author":"Stutvoet","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0580","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2967\/jnumed.117.199596","article-title":"Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression","volume":"59","author":"Donnelly","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1617487","article-title":"Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities","volume":"19","author":"Lee","year":"2025","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.bioorg.2026.110519_bb0590","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3948873","article-title":"Could fibroblast activation protein (FAP)-specific radioligands be considered as pan-tumor agents?","volume":"2022","author":"Roustaei","year":"2022","journal-title":"Contrast Media Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0595","article-title":"FAPI-PET\/CT in cancer imaging: a potential novel molecule of the century","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0600","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0605","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1007\/s00259-025-07277-0","article-title":"Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [(18)F]FDG in gynaecological malignancies: systematic literature review and meta-analysis","volume":"52","author":"Florit","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0610","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1007\/s00330-024-10843-z","article-title":"Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis","volume":"34","author":"Tang","year":"2024","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26051978","article-title":"Diagnostic performance of radiolabelled FAPI versus [(18)F]FDG PET imaging in hepato-pancreato-biliary oncology: a systematic review and meta-analysis","volume":"26","author":"Henrar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110519_bb0620","doi-asserted-by":"crossref","first-page":"71","DOI":"10.21037\/qims-2025-1196","article-title":"The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis","volume":"16","author":"Zou","year":"2026","journal-title":"Quant. Imaging Med. Surg."},{"key":"10.1016\/j.bioorg.2026.110519_bb0625","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00259-025-07576-6","article-title":"Revealing the hidden: a systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions","volume":"53","author":"Sadeghpour","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0630","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4103\/jcrt.jcrt_1144_25","article-title":"Comparative diagnostic efficacy of 18F-FDG and FAPI PET\/CT in primary liver cancers: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2025","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.bioorg.2026.110519_bb0635","first-page":"77","article-title":"Diagnostic performance of FAPI PET\/CT vs. (18)F-FDG PET\/CT in evaluation of liver tumors: a systematic review and Meta-analysis","volume":"33","author":"Singh","year":"2024","journal-title":"Mol. Imaging Radionucl. Ther."},{"key":"10.1016\/j.bioorg.2026.110519_bb0640","first-page":"44","article-title":"Diagnostic value of (18)F-FDG and (68)Ga-FAPI in head and neck cancers: a systematic review and meta-analysis","volume":"28","author":"Ma","year":"2025","journal-title":"Hell. J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/ph16121664","article-title":"Diagnostic accuracy of [(68)Ga]Ga labeled fibroblast-activation protein inhibitors in detecting head and neck cancer lesions using positron emission tomography: a systematic review and a meta-analysis","volume":"16","author":"Rizzo","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0650","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/02841851241297836","article-title":"Comparison of 68Ga-FAPI PET CT\/MRI and 18F-FDG PET\/CT in metastatic lesions of gynecological cancers: a systematic review and head-to-head meta-analysis","volume":"66","author":"Sun","year":"2025","journal-title":"Acta Radiol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0655","first-page":"35","article-title":"Head to head comparison of (68)Ga-FAPI PET\/CT with (18)F-FDG PET\/CT in primary and metastatic lesions of gastric tumor: a systematic review and meta-analysis","volume":"27","author":"Gao","year":"2024","journal-title":"Hell. J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2025.1589903","article-title":"The role of FAPI PET\/CT in patients with lymphoma: a systematic review","volume":"5","author":"Quartuccio","year":"2025","journal-title":"Front. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0665","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","article-title":"Characterization of the benign lesions with increased (68)Ga-FAPI-04 uptake in PET\/CT","volume":"35","author":"Zheng","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0670","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","article-title":"Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging","volume":"79","author":"Schmidkonz","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bioorg.2026.110519_bb0675","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00259-010-1473-6","article-title":"111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging","volume":"37","author":"Bombardieri","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0680","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 and (18)F-FDG in delayed PET\/CT imaging in prostate cancer diagnosis","volume":"15","author":"Hu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0685","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030651","article-title":"Affibody molecules as targeting vectors for PET imaging","volume":"12","author":"Tolmachev","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0690","article-title":"A biodegradable D-\u03c0-A structured hemicyanine for constructing tumor-targeted nanoplatform by Cu-64 PET\/NIR-II fluorescent\/photoacoustic imaging-guided photodynamic and photothermal therapy","author":"Chen","year":"2026","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110519_bb0695","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/1061186X.2015.1009075","article-title":"Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells","volume":"23","author":"Noaparast","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bioorg.2026.110519_bb0700","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.nucmedbio.2013.07.004","article-title":"A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors","volume":"40","author":"Varmira","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2026.110519_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102483","article-title":"Albumin-conjugation enables improved tumor targeting of aptamers via SPECT imaging","volume":"36","author":"Yang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bioorg.2026.110519_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106785","article-title":"A novel (68)Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors","volume":"140","author":"Ge","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110519_bb0715","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2967\/jnumed.123.266847","article-title":"Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-Low breast cancer with [(68)Ga]Ga-ABY-025: results from a pilot study","volume":"65","author":"Altena","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112899","article-title":"Imaging properties and tumor targeting of (68)Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients","volume":"10","author":"Gruber","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.110519_bb0725","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00259-015-3232-1","article-title":"Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET\/CT","volume":"43","author":"Maina","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110519_bb0730","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s12149-025-02093-w","article-title":"Evaluating the diagnostic utility of [68Ga]Ga-Pentixafor in solid tumors: a systematic review","volume":"39","author":"Ruzzeh","year":"2025","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0735","first-page":"939","article-title":"Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer","volume":"10","author":"Divgi","year":"1996","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0740","first-page":"625","article-title":"Diagnostic use of radiolabeled antibodies for cancer","volume":"9","author":"Harrison","year":"1995","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.bioorg.2026.110519_bb0745","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110519_bb0750","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(25)00299-2","article-title":"[(68)Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial","volume":"26","author":"Pabst","year":"2025","journal-title":"Lancet Oncol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:35:00Z","timestamp":1791261300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":150,"alternative-id":["S0045206826010552"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110519","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110519"}}